Literature DB >> 15899794

Gene expression profiling and genetic markers in glioblastoma survival.

Jeremy N Rich1, Christopher Hans, Beatrix Jones, Edwin S Iversen, Roger E McLendon, B K Ahmed Rasheed, Adrian Dobra, Holly K Dressman, Darell D Bigner, Joseph R Nevins, Mike West.   

Abstract

Despite the strikingly grave prognosis for older patients with glioblastomas, significant variability in patient outcome is experienced. To explore the potential for developing improved prognostic capabilities based on the elucidation of potential biological relationships, we did analyses of genes commonly mutated, amplified, or deleted in glioblastomas and DNA microarray gene expression data from tumors of glioblastoma patients of age >50 for whom survival is known. No prognostic significance was associated with genetic changes in epidermal growth factor receptor (amplified in 17 of 41 patients), TP53 (mutated in 11 of 41 patients), p16INK4A (deleted in 15 of 33 patients), or phosphatase and tensin homologue (mutated in 15 of 41 patients). Statistical analysis of the gene expression data in connection with survival involved exploration of regression models on small subsets of genes, based on computational search over multiple regression models with cross-validation to assess predictive validity. The analysis generated a set of regression models that, when weighted and combined according to posterior probabilities implied by the statistical analysis, identify patterns in expression of a small subset of genes that are associated with survival and have value in assessing survival risks. The dominant genes across such multiple regression models involve three key genes-SPARC (Osteonectin), Doublecortex, and Semaphorin3B-which play key roles in cellular migration processes. Additional analysis, based on statistical graphical association models constructed using similar computational analysis methods, reveals other genes which support the view that multiple mediators of tumor invasion may be important prognostic factor in glioblastomas in older patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15899794     DOI: 10.1158/0008-5472.CAN-04-3936

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  120 in total

1.  A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study.

Authors:  Warren P Mason; Mary Macneil; Petr Kavan; Jacob Easaw; David Macdonald; Brian Thiessen; Shweta Urva; Zarnie Lwin; Lynn McIntosh; Elizabeth Eisenhauer
Journal:  Invest New Drugs       Date:  2011-12-09       Impact factor: 3.850

2.  Enhancing diagnosis, prognosis, and therapeutic outcome prediction of gliomas using genomics.

Authors:  Mahfoud Assem; Zita Sibenaller; Supreet Agarwal; Maha S Al-Keilani; Mohammad A Y Alqudah; Timothy C Ryken
Journal:  OMICS       Date:  2012-03

Review 3.  Studying a complex tumor: potential and pitfalls.

Authors:  Siyuan Zheng; Milan G Chheda; Roel G W Verhaak
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

Review 4.  Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization.

Authors:  Andrew J Sawyer; Themis R Kyriakides
Journal:  Adv Drug Deliv Rev       Date:  2016-01-04       Impact factor: 15.470

Review 5.  Impact of molecular profiling on clinical trial design for glioblastoma.

Authors:  Arnab Chakravarti; Erin Tyndall; Kamalakannan Palanichamy; Minesh Mehta; Kenneth Aldape; Jay Loeffler
Journal:  Curr Oncol Rep       Date:  2007-01       Impact factor: 5.075

6.  A bayesian analysis strategy for cross-study translation of gene expression biomarkers.

Authors:  Joseph Lucas; Carlos Carvalho; Mike West
Journal:  Stat Appl Genet Mol Biol       Date:  2009-02-04

7.  Gene expression profiling of human gliomas reveals differences between GBM and LGA related to energy metabolism and notch signaling pathways.

Authors:  Javier Margareto; Olatz Leis; Eider Larrarte; Miguel A Idoate; Alejandro Carrasco; José Vicente Lafuente
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 3.444

8.  Genomic landscape of meningiomas.

Authors:  Yohan Lee; Jason Liu; Shilpa Patel; Timothy Cloughesy; Albert Lai; Haumith Farooqi; David Seligson; Jun Dong; Linda Liau; Donald Becker; Paul Mischel; Soheil Shams; Stanley Nelson
Journal:  Brain Pathol       Date:  2009-11-20       Impact factor: 6.508

9.  A network model of a cooperative genetic landscape in brain tumors.

Authors:  Markus Bredel; Denise M Scholtens; Griffith R Harsh; Claudia Bredel; James P Chandler; Jaclyn J Renfrow; Ajay K Yadav; Hannes Vogel; Adrienne C Scheck; Robert Tibshirani; Branimir I Sikic
Journal:  JAMA       Date:  2009-07-15       Impact factor: 56.272

10.  High frequency of temperature-sensitive mutants of p53 in glioblastoma.

Authors:  Jana Smardova; Kvetoslava Liskova; Barbora Ravcukova; Lenka Kubiczkova; Sabina Sevcikova; Jaroslav Michalek; Miluse Svitakova; Vaclav Vybihal; Leos Kren; Jan Smarda
Journal:  Pathol Oncol Res       Date:  2013-03-28       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.